Evidence map›Paper›PMID 35574602›Full record

ReviewCritical reviews in microbiology2023

Probiotics: insights and new opportunities for

Rusha Pal, Ahmad I M Athamneh, Riddhi Deshpande, Jose A R Ramirez, Kayode T Adu, Pushpanathan Muthuirulan, Shrikant Pawar, Manuele Biazzo, Yiorgos Apidianakis, Ulrik Kraemer Sundekilde and 4 more

Open access · greenAbstract readReview
In one paragraph

Review in Critical reviews in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Analytical chemistry · 2025
    Article
  12. Review
  13. Review
  14. Review
  15. Non-invasive treatment ofFrontiers in microbiology · 2025
    Article
  16. Review
  17. Efficacy and Safety of a Probiotic ContainingJournal of clinical medicine · 2024
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 4 countries.

Rusha PalDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Ahmad I M AthamnehDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA.
Riddhi DeshpandeReading Hospital, Tower Health, West Reading, PA, USA.
Jose A R RamirezProbioWorld Consulting Group, James Cook University, Queensland, Australia.
Kayode T AduProbioWorld Consulting Group, James Cook University, Queensland, Australia.
Pushpanathan MuthuirulanDepartment of Human Evolutionary Biology, Harvard University, Cambridge, MA, USA.
Shrikant PawarThe Anlyan Center Yale Center for Genomic Analysis, Yale School of Medicine, New Haven, CT, USA.
Manuele BiazzoThe Bioarte Ltd Laboratories at Life Science Park, San Gwann, Malta.
Yiorgos ApidianakisDepartment of Biological Sciences, University of Cyprus, Nicosia, Cyprus.
Ulrik Kraemer SundekildeDepartment of Food Science, Aarhus University, Aarhus, Denmark.
Cesar de la Fuente-NunezDepartments of Psychiatry and Microbiology, Machine Biology Group, Institute for Biomedical Informatics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Mark G MartensReading Hospital, Tower Health, West Reading, PA, USA.
George P TegosDrexel University College of Medicine, Philadelphia, PA, USA.
Mohamed N SeleemDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.ORCID 0000-0003-0939-0458
Reading Hospital · USVirginia–Maryland College of Veterinary Medicine · USAarhus University · DKDrexel University · USHarvard University · USJames Cook University · AUPurdue University West Lafayette · USTranslational Therapeutics (United States) · USUniversity of Cyprus · CYWalter and Eliza Hall Institute of Medical Research · AUYale Cancer Center · US

Funding

Repurposing novel selective drugs for treatment and decolonization of vancomycin resistant enterococciR01AI148523 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Daniel Patrick Flaherty, Mohamed Seleem · 2019 to 2026
$4.2M
Repurposing auranofin and ebselen for treatment of multidrug resistant pathogensR01AI130186 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI SELEEM, MOHAMED · 2017 to 2021
$2.3M
NIAID NIH HHS R01 AI130186NIAID NIH HHS R01 AI148523
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Clostridioides difficileClostridium InfectionsProbioticsAnti-Bacterial AgentsClostridioidesHumansVancomycinAnti-Bacterial AgentsVancomycinC. difficilediscovery informaticsgenomic explorationimmunomodulatoryinhibitionmetabolomicsmulti-omicsProbioticsregulatory requirementsvirulence

Identifiers

PMID35574602
PMCPMC9743071
OpenAlexW4280512542

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.